Salute e Benessere

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington’s disease (HD). Though final meeting minutes have not yet been received, based on the discussions at the meeting, uniQure believes that...
Nasdaq GlobeNewswire
03/11/2025

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L1 1and VEGF-A, in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer Plan to initiate...
Nasdaq GlobeNewswire
03/11/2025

TCT 2025 | Robot-Assisted PCI Enters a New Era: Results of the PANVIS STAR…

In traditional PCI procedures, vascular interventional physicians must wear heavy lead aprons and operate for extended periods under X-ray, facing multiple occupational risks such as an increased incidence of orthopedic and ophthalmic diseases. With the advancement of precision medicine and telemedicine, robot-assisted PCI has become a key pathway to address these challenges. However, most current interventional robots rely on joystick control, making it difficult to simulate physicians'…
PR Newswire
03/11/2025

Pulsenmore Receives FDA De Novo Marketing Authorization for Home-Use Prenatal…

The Pulsenmore ES integrates at-home ultrasound imaging into physician-led prenatal care. The Pulsenmore cradle connects to the patient's smartphone and guides her step-by-step via the Pulsenmore app. Captured video clips are securely transmitted to physicians for review and interpretation on a dedicated dashboard. Pulsenmore's U.S. clinical validation was achieved through a multi-center trial conducted at four leading academic and clinical institutions. The Pulsenmore ES integrates at-home...
PR Newswire
03/11/2025

Naturecan Welcomes FDA NMN Ruling, Unlocking New Global Opportunities

Naturecan, a global wellness brand committed to science-backed innovation, sees this as a pivotal moment for the future of nutrition. Naturecan, a global wellness brand committed to science-backed innovation, sees this as a pivotal moment for the future of nutrition. "The FDA's re-evaluation of NMN is a global milestone. It demonstrates growing recognition of NMN as a trusted supplement ingredient and opens the door for consumers in the U.S. to access it more easily again," said…
PR Newswire
03/11/2025

PureHealth Delivers Strong 9-Month Results with AED 20.1 Billion in Revenue and…

The transaction was funded through PureHealth's strong balance sheet, underscoring the Group's financial strength as it continues to scale and pursue strategic growth opportunities. Financial contributions from the acquisition are being recognised from 1 October 2025, reflecting the group's continued international expansion and operational scale. PureHealth now holds 52% of its assets outside UAE. The transaction was funded through PureHealth's strong balance sheet, underscoring the Group's...
PR Newswire
03/11/2025

Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for…

Helping European Biotechs Accelerate Early Phase Success With Faster Timelines, Lower Costs, and Globally Accepted Data Avance Clinical, the largest premium full-service Australian headquartered CRO with more than 30 years of early phase expertise, is highlighting its Early Phase Center of Excellence for Biotechs and the well-established Australian Advantage to European biotechs ahead ofBIO-Europe in Vienna, November 3-5, 2025.European biotechs under increasing investor and...
Nasdaq GlobeNewswire
03/11/2025

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical…

LONDON and MILAN, Nov.03, 2025(GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 million (€122 million) Series B financing round.The round was co-led by a new lead, Schroders Capital, as well as existing investors Atlas Venture and Forbion. Other new investors included Amgen Ventures, Athos Capital, CDP Venture Capital through its Large...
Nasdaq GlobeNewswire
03/11/2025

ArisGlobal Announces NavaX™ Agents Suite

Building on ArisGlobal's long-standing commitment to AI with purpose, NavaX Agents represent a new generation of autonomous, domain-trained digital agents designed to reason, act, and collaborate within the LifeSphere Unify platform. Each Agent is built to perform specialized, high-impact tasks—continuously learning from human input and organizational context to provide intelligence and insights like never before, while delivering even greater accuracy, efficiency, and compliance. Building on...
PR Newswire
03/11/2025

Sandstone Easydrip™ Plus with Hextra Tech™ Hexagonal Broad Hub Delivers…

What sets Easydrip™ Plus apart What sets Easydrip™ Plus apart Why it matters Pen-needle stability and comfort directly influence user confidence and adherence. A hub that resists tilt can minimize off-target delivery and help make frequent self-injections feel more manageable—outcomes Easydrip™ Plus is designed to support. Regulatory snapshot About Sandstone and SteriLance Sandstone Medical is the diabetes-care brand of SteriLance Medical, developing pen needles, safety...
PR Newswire
03/11/2025

Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in…

"Alzheimer's disease is one of the world's most urgent healthcare challenges. Advances in early diagnosis, combined with treatments that enable earlier intervention, hold the potential to transform how we approach Alzheimer's, as well as other forms of dementia," ATx founder Dr. Hakon Hakonarson said. "Through our clinical trials targeting both rare and common forms of dementia, we are pushing the science forward with the goal of not only delaying progression, but ultimately…
PR Newswire
03/11/2025

Vivoryon Therapeutics N.V. to Present at Upcoming Conferences

Vivoryon Therapeutics N.V. to Present at Upcoming ConferencesHalle (Saale) / Munich, Germany, November 3 , 2025- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November: American Society of...
Nasdaq GlobeNewswire
03/11/2025

IBA integrates Artificial Intelligence Quality Assurance into dosimetry…

Dosimetry portfolio strengthened with Medical Imaging QA and AI validation Louvain-la-Neuve, Belgium, 03 November 2025- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance.Founded in 2018 by Dr...
Nasdaq GlobeNewswire
03/11/2025

Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction…

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwideIf approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity 1 These...
Nasdaq GlobeNewswire
03/11/2025

Alvotech Provides Update on the Status of U.S. Biologics License Application for…

REYKJAVIK, ICELAND (November 2, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab).The CRL noted that certain...
Nasdaq GlobeNewswire
02/11/2025

Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the…

COPENHAGEN, Denmark, November 1, 2025– Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and Response Authority (HERA) framework agreement, announced yesterday, and the Public Preparedness business.The initial order for 750,000 doses of MVA-BN smallpox/mpox vaccine that was announced yesterday will be delivered in 2026 and is the result of a new joint procurement contract by the European Commission, through the HERA. This represents...
Nasdaq GlobeNewswire
01/11/2025

Cellectis to Report Third Quarter Financial Results on November 7, 2025

The press release will be available in the Investors section of Cellectis’ website:https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions atinvestors@cellectis.comAbout CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic...
Nasdaq GlobeNewswire
31/10/2025

Teva to Present at UBS Global Healthcare Conference and Jefferies London…

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows: UBS Global Healthcare Conference Monday, November 10, 2025, at 8:45 A.M. Eastern Time (ET)Jefferies London Healthcare Conference Tuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET) To access a live webcast of the presentation, visit Teva’s Investor Relations website...
Nasdaq GlobeNewswire
31/10/2025

Fagron’s share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 27 October 2025 through 31 October 2025, Fagron purchased 46,000 of its owns shares at an average price of €20.5831 per share corresponding to a total amount of €946,821.80. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
31/10/2025

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

COPENHAGEN, Denmark, October 31, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.99% of the shares and voting rights in Bavarian Nordic A/S as of October 27, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...
Nasdaq GlobeNewswire
31/10/2025

Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the initiation of a new research and development program leveraging nanotechnology to enhance the effectiveness of phytochemical constituents used in its dietary supplement formulas.This new initiative builds upon the proprietary know-how developed during the creation of CCX Hydrogel, a breakthrough platform for optimised bioactive...
Nasdaq GlobeNewswire
31/10/2025

Disposable Endoscopes Market worth $2.67 billion by 2030 with 22.9% CAGR |…

Browse in-depth TOC on "Disposable Endoscopes Market" Browse in-depth TOC on "Disposable Endoscopes Market" 250 - Tables 60 - Figures 350 - Pages By type,the disposable endoscopes market is segmented into urology endoscopes, bronchoscopes, cystoscopes, laryngoscopes, GI endoscopes, arthroscopes, and other disposable endoscopes. Among these, the urology endoscopes segment held the largest market share in 2024, due to the rising prevalence of chronic kidney and ureteral...
PR Newswire
31/10/2025

Pet Perfume Market to Reach $2.7 billion, Globally, by 2034 at 6.7% CAGR: Allied…

Expanding product visibility through targeted marketing campaigns, celebrity associations with grooming product lines, and strong influence from pet-focused social media content have significantly raised awareness around pet perfume. In addition, the inclusion of pet perfume in grooming service bundles at parlors and spas has normalized regular usage. Manufacturers continue to introduce multipurpose products combining odor control with soothing or insect-repelling ingredients to address specific…
PR Newswire
31/10/2025

Bavarian Nordic shareholders are reminded of expiry of the offer period…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, 31 October, 2025– Reference is made to the company announcements dated 26 August 2025 (no. 24/2025), 29 September 2025 (no. 27/2025), 15 October 2025 (no. 31/2025), and 21 October 2025 (no. 33/2025) regarding the all-cash voluntary recommended public takeover offer to...
Nasdaq GlobeNewswire
31/10/2025
Altri  Comunicati